Glycosaminoglycan mimetics: A therapeutic approach to cerebral amyloid angiopathy

Amyloid

Volumn 8, Issue SUPPL. 1, 2001, Pages 28-35

  Gervais, F ^a   Chalifour, R ^a   Garceau, D ^a   Kong, X ^a   Laurin, J ^a   McLaughlin, R ^a   Morissette, C ^a   Paquette, J ^a  

^a Neurochem Inc   (Canada)

Author keywords

A protein; Alzheimer's disease glycosaminoglycan; Cerebral amyloid angiopathy

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; GLYCOSAMINOGLYCAN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD VESSEL RUPTURE; BRAIN HEMORRHAGE; CONFERENCE PAPER; CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; VASCULAR AMYLOIDOSIS;

AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; CELLS, CULTURED; CEREBRAL AMYLOID ANGIOPATHY; CIRCULAR DICHROISM; GLYCOSAMINOGLYCANS; HUMANS; KINETICS; MICE; MICROSCOPY, ELECTRON; MOLECULAR MIMICRY; RATS;

EID: 0034820554     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Cerebral amyloid angiopathy: The vascular pathology and complications
2. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study
3. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy
4. Pathologic process leading to cerebral hemorrhage in amyloid angiopathy
5. Visualization of A beta monoclonals: Evidence that an initially deposited species is A beta 42(43)
6. Amyloid beta protein (a-beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at a-beta40 or a-beta-42(43)
7. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome
8. Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum
9. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease
10. Rapid degeneration of cultured human brain pericytes by amyloid β protein
11. Enhanced pathologic properties of Dutch-type mutant amyloid β-protein
12. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses
13. Proteoglycan in amyloidogenesis
14. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation
15. The sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide fibril formation
16. Proteoglycan-mediated inhibition of Aβ proteolysis. A potential cause of senile plaque accumulation
17. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain
18. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis
19. Aβ amyloidogenesis: Unique, or variation on a systemic theme?
20. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
21. Binding of heparan sulphate glycosaminoglycan to beta-amyloid peptide: Inhibition by potentially therapeutic polysulphated compounds
22. Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons
23. 51Cr release
24. Sulphated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells
25. Potent inhibition of scrapie-associated PrP accumulation by Congo Red
26. Scrapie associated PrP accumulation and its prevention - Insights from cell culture
27. Inhibition of amyloidogenesis with Congo red in experimental amyloidosis
28. Congo Red protects against toxicity of β-amyloid peptides on rat hippocampla neurones
29. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red
30. Sulphated compounds attenuate β-amyloid toxicity by inhibiting its association with cells